Novartis bags FDA priority review in tight lung cancer race against Merck KGaA
admin 11th February 2020 Uncategorised 0At last year’s American Society of Clinical Oncology meeting, both Novartis and Merck KGaA rolled out data for their drugs aimed at MET exon 14 skipping-mutated non-small cell lung cancer. Now thanks to an FDA priority review for capmatinib, Novartis is one step ahead.
More: Novartis bags FDA priority review in tight lung cancer race against Merck KGaA
Source: fierce